Recursion [RXRX] vs Tempus AI [TEM] Detailed Stock Comparison
Recursion
NASDAQ
Loading...
Tempus AI
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 18 vital metrics comparison: Recursion wins in 6 metrics, Tempus AI wins in 11 metrics, with 0 ties. Tempus AI appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Recursion | Tempus AI | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -3.33 | 33.14 | Recursion |
| Price-to-Book Ratio | 2.68 | 39.94 | Recursion |
| Debt-to-Equity Ratio | 9.58 | 275.63 | Recursion |
| PEG Ratio | -0.48 | -0.34 | Recursion |
| EV/EBITDA | -3.27 | -74.58 | Tempus AI |
| Profit Margin (TTM) | 22.65% | -20.98% | Recursion |
| Operating Margin (TTM) | -916.75% | -19.00% | Tempus AI |
| Return on Equity | -86.34% | -97.95% | Recursion |
| Return on Assets (TTM) | -39.08% | -11.51% | Tempus AI |
| Free Cash Flow (TTM) | $-376.22M | $-211.17M | Tempus AI |
| 1-Year Return | -16.32% | 40.70% | Tempus AI |
| Price-to-Sales Ratio (TTM) | 38.31 | 13.00 | Tempus AI |
| Enterprise Value | $1.91B | $12.09B | Tempus AI |
| EV/Revenue Ratio | 29.64 | 12.70 | Tempus AI |
| Gross Profit Margin (TTM) | -5.54% | 61.99% | Tempus AI |
| Revenue per Share (TTM) | $0 | $6 | Tempus AI |
| Earnings per Share (Diluted) | $-1.81 | $2.15 | Tempus AI |
| Beta (Stock Volatility) | 0.92 | N/A | N/A |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Recursion vs Tempus AI Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Recursion | -1.05% | 4.25% | 6.82% | 30.86% | -46.44% | -21.78% |
| Tempus AI | 2.81% | 21.88% | 23.82% | 10.51% | -19.96% | 109.02% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Recursion | -16.32% | -42.45% | -81.98% | -81.98% | -81.98% | -81.98% |
| Tempus AI | 40.70% | 77.86% | 77.86% | 77.86% | 77.86% | 77.86% |
Performance & Financial Health Analysis: Recursion vs Tempus AI
| Metric | RXRX | TEM |
|---|---|---|
| Market Information | ||
| Market Cap | $2.47B | $12.38B |
| Market Cap Category | Mid cap | Large cap |
| 10 Day Avg. Volume | 19,758,072 | 9,388,110 |
| 90 Day Avg. Volume | 28,076,457 | 8,782,537 |
| Last Close | $5.64 | $71.59 |
| 52 Week Range | $3.79 - $12.36 | $31.36 - $91.45 |
| % from 52W High | -54.37% | -21.72% |
| All-Time High | $42.81 (Jul 12, 2021) | $91.45 (Feb 10, 2025) |
| % from All-Time High | -86.83% | -21.72% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.33% | 0.90% |
| Quarterly Earnings Growth | 0.33% | 0.90% |
| Financial Health | ||
| Profit Margin (TTM) | 0.23% | -0.21% |
| Operating Margin (TTM) | -9.17% | -0.19% |
| Return on Equity (TTM) | -0.86% | -0.98% |
| Debt to Equity (MRQ) | 9.58 | 275.63 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $2.12 | $1.78 |
| Cash per Share (MRQ) | $1.21 | $1.68 |
| Operating Cash Flow (TTM) | $-383,030,016 | $-52,047,000 |
| Levered Free Cash Flow (TTM) | $-186,021,744 | $18.93M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Recursion vs Tempus AI
| Metric | RXRX | TEM |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -3.33 | 33.14 |
| Forward P/E | -3.29 | -101.79 |
| PEG Ratio | -0.48 | -0.34 |
| Price to Sales (TTM) | 38.31 | 13.00 |
| Price to Book (MRQ) | 2.68 | 39.94 |
| Market Capitalization | ||
| Market Capitalization | $2.47B | $12.38B |
| Enterprise Value | $1.91B | $12.09B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 29.64 | 12.70 |
| Enterprise to EBITDA | -3.27 | -74.58 |
| Risk & Other Metrics | ||
| Beta | 0.92 | N/A |
| Book Value per Share (MRQ) | $2.12 | $1.78 |
Financial Statements Comparison: Recursion vs Tempus AI
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | RXRX | TEM |
|---|---|---|
| Revenue/Sales | $19.10M | $255.74M |
| Cost of Goods Sold | $20.16M | $100.53M |
| Gross Profit | $-1.06M | $155.20M |
| Research & Development | $128.64M | $69.27M |
| Operating Income (EBIT) | $-176.23M | $-68.69M |
| EBITDA | $-147.57M | $-73.98M |
| Pre-Tax Income | $-171.90M | $-112.33M |
| Income Tax | $0 | $-46.18M |
| Net Income (Profit) | $-171.90M | $-68.04M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | RXRX | TEM |
|---|---|---|
| Cash & Equivalents | $500.45M | $151.60M |
| Total Current Assets | $584.15M | $573.97M |
| Total Current Liabilities | $141.98M | $336.47M |
| Long-Term Debt | $72.47M | $848.33M |
| Total Shareholders Equity | $933.95M | $326.19M |
| Retained Earnings | $-1.63B | $-2.22B |
| Property, Plant & Equipment | $204.78M | $168.53M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | RXRX | TEM |
|---|---|---|
| Operating Cash Flow | $-143.55M | $-109.53M |
| Capital Expenditures | $-1.83M | $-2.07M |
| Free Cash Flow | $-133.79M | $-109.00M |
| Debt Repayment | $-2.05M | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | RXRX | TEM |
|---|---|---|
| Shares Short | 117.54M | 23.17M |
| Short Ratio | 3.70 | 2.59 |
| Short % of Float | 0.29% | 0.18% |
| Average Daily Volume (10 Day) | 19,758,072 | 9,388,110 |
| Average Daily Volume (90 Day) | 28,076,457 | 8,782,537 |
| Shares Outstanding | 396.51M | 161.98M |
| Float Shares | 416.17M | 101.43M |
| % Held by Insiders | 0.05% | 0.43% |
| % Held by Institutions | 0.71% | 0.42% |
Dividend Analysis & Yield Comparison: Recursion vs Tempus AI
| Metric | RXRX | TEM |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |